证券代码：600993 证券简称：马应龙 公告编号：2025-013 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合 的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 30 日14 点 00 分 召开地点：公司会议室 (五) 网络投票的系统、起止日期和投票时间。 马应龙药业集团股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次：2024年年度股东大会 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 30 日 至2025 年 6 月 30 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东 大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投 票平台的投票时间为股东大会召开当日的 9:15-15:00 ...

证券代码：600993 证券简称：马应龙 公告编号：临 2025-011 马应龙药业集团股份有限公司 第十一届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 马应龙药业集团股份有限公司（以下简称"公司"）第十一届董事会第二 十次会议于 2025 年 6 月 9 日以通讯方式召开，本次会议通知及会议材料于 2025 年 6 月 4 日以电话及电子邮件形式发出。公司九名董事均在规定时间内对本次 会议议案进行了表决，本次会议的召集、召开符合《公司法》、《公司章程》 等有关规定，会议审议通过了以下议案： 一、《关于聘任 2025 年度会计师事务所的议案》 同意：9 票，反对：0 票，弃权：0 票 公司拟续聘中审众环会计师事务所（特殊普通合伙）为 2025 年度财务审计 机构和内控审计机构。董事会审议前，该议案已经第十一届董事会审计委员会 2025 年第 4 次会议审议通过。本议案尚需提交股东大会审议。 详细内容请见公司于 2025 年 6 月 10 日在《中国证券报》、《上海证券报》和 上海证券交易所网站（ ...

二、药品的其他情况 马应龙药业集团股份有限公司 关于全资子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，马应龙药业集团股份有限公司（以下简称"公司"或"本公司"）全 资子公司江西马应龙美康药业有限公司（以下简称"马应龙美康"）收到国家药 品监督管理局核准签发的玻璃酸钠滴眼液[规格：0.3%（0.4ml:1.2mg）]（以下 简称"该药品"）《药品注册证书》（证书编号：2025S01677），现就相关情况 公告如下： 一、药品的基本情况 药品名称：玻璃酸钠滴眼液 剂型：眼用制剂 规格：0.3%（0.4ml:1.2mg） 注册分类：化学药品 4 类 药品注册标准编号：YBH12122025 处方药/非处方药：处方药 上市许可持有人：江西马应龙美康药业有限公司 生产企业：浙江赛默制药有限公司 药品批准文号：国药准字 H20254427 药品批准文号有效期：至 2030 年 06 月 02 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给 ...

关于参加湖北辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600993 证券简称：马应龙 公告编号：临 2025-010 马应龙药业集团股份有限公司 1 为进一步加强与投资者的互动交流，马应龙药业集团股份有限公司（以下简 称"公司"）将参加由湖北证监局、湖北省上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年湖北辖区上市公司投资者集体接待日活动"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号（全景财经），或下载全景路演 APP,参与 本次互动交流，活动时间为 2025 年 6 月 12 日（星期四）14:00-16:40。届时公司 高管将在线就公司经营业绩、公司治理、发展战略、经营状况等投资者关心的问 题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 马应龙药业集团股份有限公司董事会 2025 年 6 月 7 日 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 29.00 and a sector rating of "Outperform" [1][3]. Core Views - The company has demonstrated steady growth in its performance, with a 2024 revenue of RMB 3.728 billion, representing an 18.85% year-on-year increase, and a net profit of RMB 528 million, up 19.14% year-on-year. The first quarter of 2025 shows a revenue of RMB 969 million, a 1.48% increase, and a net profit of RMB 204 million, up 2.99% year-on-year. The company has a strong brand presence in the anorectal field and is expected to gain new growth from its health business [3][5]. - The company is expected to see continued growth in its health business, particularly with the launch of new products targeting the anorectal health management market, which is anticipated to enhance brand recognition and sales [8]. Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of RMB 3.728 billion, with a growth rate of 18.9%. The projected revenues for 2025, 2026, and 2027 are RMB 4.204 billion, RMB 4.720 billion, and RMB 5.250 billion, respectively, with growth rates of 12.8%, 12.3%, and 11.2% [7]. - The net profit for 2024 was RMB 528 million, with a growth rate of 19.1%. The projected net profits for the following years are RMB 616 million, RMB 714 million, and RMB 798 million, with growth rates of 16.6%, 16.0%, and 11.7% [7]. Valuation - The report slightly adjusts the profit forecast, estimating the net profit for 2025-2027 to be RMB 616 million, RMB 714 million, and RMB 798 million, respectively. The corresponding earnings per share (EPS) are projected to be RMB 1.43, RMB 1.66, and RMB 1.85. The price-to-earnings (P/E) ratios for these years are expected to be 20.3, 17.5, and 15.7 times [5][7]. Market Position - The company has a strong foothold in the anorectal market, with significant brand advantages. The health sector is anticipated to provide new growth opportunities, particularly through the introduction of innovative products and enhanced market coverage [3][8].

Core Insights - The competition in the sunscreen cosmetics market is intensifying earlier and more fiercely in 2025, with numerous new products launched by various brands, including domestic and international players [1][2] - The market size of sunscreen cosmetics in China is projected to decline from 31.37 billion yuan in 2022 to 29.78 billion yuan in 2024, but is expected to recover growth in the following years [1] - The demand for sunscreen products has become a hard requirement for Chinese consumers, with 38.82% using sunscreen daily, an increase of 12.71 percentage points since 2020 [2] Product Launches and Trends - The number of approved sunscreen products has surged, with over 2,700 products approved in 2024, compared to 1,500 in 2023 and around 900 in 2022 [1][2] - Brands are focusing on product innovation, with an emphasis on efficacy and unique technologies, such as "霓纱防晒锁妆膜" by 花西子 and "御光滤" by 蜜丝婷 [3][5] - The sunscreen base makeup segment is experiencing significant growth, with sales of sunscreen foundation increasing by 517.7% year-on-year in 2024 [5] Market Dynamics - The entry barrier for the sunscreen category is relatively high due to regulatory requirements and the need for specialized ingredient development [3] - The market is witnessing a shift towards outdoor sunscreen products, with brands like 安热沙 targeting this segment [5] - The presence of foreign brands remains dominant, but domestic brands are gaining traction by offering competitive pricing [7][8] Consumer Behavior and Marketing - Chinese consumers exhibit diverse needs for sunscreen products, focusing not only on sun protection but also on safety, texture, and additional benefits like whitening [2] - Emotional value in product design and marketing is becoming increasingly important, with brands leveraging celebrity endorsements to drive sales [6] - The rise of mid-to-high-end brands is notable, with significant sales in the 200-500 yuan price range on e-commerce platforms [8]

证券代码：600993 证券简称：马应龙 公告编号：临 2025-009 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 公司控股股东中国宝安持有本公司股份总数 126,163,313 股，占本公司总 股本的 29.27%，本次解除质押 10,000,000 股，解除质押后，中国宝安累计质押 股份 90,000,000 股, 占其持有本公司股份总数的 71.34%，占本公司总股本的 20.88%。 2025 年 5 月 29 日，马应龙药业集团股份有限公司（以下简称"公司"或"本 公司"）接控股股东中国宝安集团股份有限公司（以下简称"中国宝安"）函告， 2025 年 5 月 28 日中国宝安在中国证券登记结算有限责任公司与中国银行股份有 限公司深圳罗湖支行办理了本公司 10,000,000 股无限售流通股解除质押手续，具 体情况如下： | 股东名称 | 中国宝安集团股份有限公司 | | | | --- | --- | --- | --- | | 本次解除质押股份（股） | 10,000,000 | | | | ...

Group 1 - The controlling shareholder, China Baoan, holds a total of 126 million shares in the company, accounting for 29.27% of the total share capital [1] - A total of 10 million shares have been released from pledge, resulting in China Baoan having 90 million pledged shares, which represents 71.34% of its total holdings in the company and 20.88% of the company's total share capital [1] - The release of the pledge is effective from May 28, 2025 [1]

Core Viewpoint - The company plans to hold a performance briefing on June 6, 2025, to discuss its 2024 annual report and the first quarter report of 2025, allowing investors to engage and ask questions [2][3]. Group 1: Meeting Details - The performance briefing is scheduled for June 6, 2025, from 10:30 AM to 11:30 AM [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live streaming and online interaction [4]. - Investors can submit questions from May 29, 2025, to June 5, 2025, before 4:00 PM through the Roadshow Center website or via the company's email [2][5]. Group 2: Participants - Key participants in the meeting include Chairman Chen Ping, General Manager Xia Youzhang, and other senior executives [4]. Group 3: Investor Participation - Investors can join the performance briefing online on June 6, 2025, and the company will address commonly asked questions during the session [5]. - After the briefing, investors can access the meeting's details and main content through the Roadshow Center [5].

Core Viewpoint - The company, Mayinglong Pharmaceutical Group Co., Ltd., is set to hold a performance briefing on June 6, 2025, to discuss its 2024 annual results and Q1 2025 performance, allowing for investor interaction and questions [1][2]. Group 1: Meeting Details - The performance briefing is scheduled for June 6, 2025, from 10:30 AM to 11:30 AM [2][3]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible via the website: https://roadshow.sseinfo.com/ [2][3]. - The format of the meeting will be a combination of video and online interaction, enabling real-time communication with investors [2][3]. Group 2: Participation Information - Investors can submit questions from May 29, 2025, to June 5, 2025, by visiting the "Pre-Question Collection" section on the Shanghai Stock Exchange Roadshow Center website or by emailing ir@mayinglong.cn [3]. - During the briefing, the company will address commonly asked questions from investors within the scope of information disclosure [2][3]. Group 3: Key Personnel - Key participants in the meeting will include Chairman Chen Ping, General Manager Xia Youzhang, Secretary of the Board Ma Qian, CFO Mao Tao, and Independent Director Mao Peng [2].